Best Mounjaro Dose Tracker Apps for 2026
6 min read
CEO & Co-Founder of miora. Consumer health growth expert.
Tracking Mounjaro is simple in week one and harder in week sixteen. The pen tells you the dose; what it does not tell you is whether the side-effect curve is widening, whether the next titration is going to be tolerable, or whether protein intake has quietly drifted below the muscle-protection threshold. This is the comparison of tools that actually surface that pattern.
Topics on this page
The Mounjaro pen tells you the dose; it does not tell you whether the side-effect curve is widening. The widening is the signal that the next titration may not be tolerated.
Protein intake is the most-missed daily metric on Mounjaro. Appetite suppression makes it easy to drop below 1.6 g/kg lean body mass without noticing.
Raw daily weight is noise. A 14-day moving average is the only weight signal that reflects actual loss versus water and stool weight.
Mounjaro is the cleanest GLP-1 to track on paper. Weekly injection, pen-delivered, six fixed dose steps from 2.5 mg up to 15 mg. The complication is not the dose - it is everything that happens between the doses. The nausea curve shifts at each titration. Protein intake silently drops because appetite suppression is doing its job. The scale fluctuates day to day on water and stool weight in a way that obscures the actual loss trend. By week sixteen, the user who has not been logging is making decisions on vibes. This guide walks what to track, what to skip, and how miora handles the daily check in iMessage.
Mounjaro (tirzepatide for type 2 diabetes) is a dual GIP/GLP-1 receptor agonist. The pen delivers fixed doses in six steps: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The standard titration is one step every four weeks, slower if side effects warrant. The dose progression and the brand both make the basic logging straightforward - you know exactly what you injected and when - and the tracking burden moves from 'what was the dose' to 'how is the dose being tolerated.'
Three Mounjaro-specific patterns the tracker needs to capture. First, the dual GIP/GLP-1 mechanism produces a slightly different side-effect profile than pure GLP-1 agonists - typically less peak nausea but more variability in fatigue and a more pronounced early-titration GI shift. Second, the four-week titration interval means each step has its own multi-week side-effect curve, and the curve at the new step is what determines whether the next step is reasonable. Third, the dose ceiling for Type 2 diabetes is 15 mg; users running Mounjaro off-label for weight management often hit that ceiling and then need different signals to decide whether to stay there or step down.
The within-week pattern across Mounjaro cycles is fairly consistent. Day 0 is the injection. Day 1-2 typically shows the peak GI and nausea response. Day 2-3 is the energy dip. Day 4-5 is recovery. Day 6 is baseline. This curve shifts at each titration: at the 2.5 mg step it is often barely noticeable; at 7.5 and above the curve is the dominant feature of the week.
The actionable data is not the average. It is the day-1-and-day-2 score relative to the previous step. If day-1 nausea was 2-out-of-5 at the 5 mg step and is 4-out-of-5 at the 7.5 mg step, the next titration to 10 is likely to push the curve past tolerable. A tracker that does not capture day-relative scores cannot make this prediction.
The across-week pattern matters as much. By the third week at a new step, most users see the curve compress - day-1 nausea drops, the day-2-3 energy dip narrows. If the curve does not compress by week three at a new step, that is itself a flag worth bringing to the prescriber.
The single most under-tracked thing on Mounjaro is daily protein intake. Mounjaro suppresses appetite effectively; by the second or third step most users are eating substantially less, and the calories go down in a way that feels effortless. The hidden cost is that protein intake often drops below the muscle-protection threshold without the user noticing.
The threshold for muscle preservation during weight loss on a GLP-1 is approximately 1.6 g/kg lean body mass, with some clinicians targeting closer to 2.0 g/kg for older or more deconditioned populations. For a 75 kg adult with 55 kg lean mass, that is roughly 90 to 110 g of protein per day, every day. Two weeks of 50 g per day - which is easy to hit when total intake is suppressed - is the start of measurable muscle loss alongside the fat loss.
A tracker that does not capture daily protein in grams is silent on the most important muscle-preservation lever. The muscle-preservation guide walks the protein, resistance training, and DEXA-tracking protocol that goes alongside the Mounjaro cycle.
Day-to-day weight on a Mounjaro cycle is noise. A typical day-to-day swing of 1.5 to 2 lbs is normal water and stool-weight variation; it has nothing to do with whether the protocol is working. The signal lives in the 7-day or 14-day moving average. A tracker that shows you raw daily weight without smoothing is producing anxiety rather than data.
The right view is the smoothed trend line with the daily points faded in the background. The smoothed line moves more slowly and tells you the actual rate of loss. The honest expected rate on a tolerated Mounjaro protocol is roughly 0.5 to 1.5% of body weight per month after the first month. Faster than that and you are probably under-fueled (and the muscle loss is going to show up in the DEXA); slower than that and the protocol is hitting a stall worth investigating.
Without smoothing, the user looks at the scale on a high day and assumes the protocol stopped working. The smoothed trend would have shown that the underlying line is still descending. This is the scale-anxiety pattern that drives unnecessary protocol changes.
The daily flow for a Mounjaro user is one text in the evening: 'Mounjaro check, day N post-injection: nausea / fatigue / GI / hydration oz / protein g / weight if logged?' A typical reply: '2 3 OK 64 105 187.4' or 'mild nausea, normal energy, GI fine, 64 oz, hit protein, scale 187.4.' miora parses both.
The injection-day event is logged in a separate text: 'injected Mounjaro 7.5 mg, left thigh, 8:14 a.m.' miora confirms the dose step, the next planned titration date, and notes the rotation pattern (Mounjaro injection sites should rotate to avoid lipohypertrophy, and most users do not track which thigh they used last week).
The weekly summary maps the day-by-day side-effect scores to the injection. A typical week-three summary at the 7.5 mg step might read: 'Day-1 nausea averaged 2.3 this step, vs 1.8 at 5 mg. Day-2-3 fatigue slightly broader. Protein hit on five of seven days. Hydration averaged 58 oz; that is the lever for next week. Smoothed weight is down 1.1 lb week-over-week. Next titration to 10 mg is on schedule and side-effect curve looks tolerable.' That is the conversation the next prescriber visit starts with.
The compound is the same as Zepbound (also tirzepatide, branded for weight management instead of T2DM). The tracking is essentially identical: same dose steps, same injection schedule, same side-effect profile. The difference is mostly insurance coverage and which prescriber writes the script. If you are switching between Mounjaro and Zepbound mid-protocol because of coverage changes - which happens often - the tracker should show this as a continuation, not a reset.
Compound tirzepatide is a different story. Vial-and-syringe, units calculated from concentration, no pen to confirm the dose. The tracker burden moves to dose math: reconstitution date, vial concentration, units per dose, and reconstitution-batch stability. The compound semaglutide guide covers the same workflow for the other major compound option. miora handles both pen-delivered branded tirzepatide and vial-delivered compound in the same thread.
The Mounjaro prescriber conversation goes faster with structured data than with a verbal report. Thresholds worth flagging:
Day-1 nausea at 4-out-of-5 for two consecutive cycles at a stable dose. The current step may be the ceiling.
Side-effect curve not compressing by week three at a new step. The titration may not be holding.
Smoothed weight loss faster than 2% of body weight per month. Worth a body-composition check; faster loss is often muscle loss.
Smoothed weight loss stalled for four weeks at the current step. Worth discussing whether to titrate or to investigate amplifiers.
Protein intake below 80 g per day for two weeks. Muscle-preservation risk.
Resting heart rate up 5+ bpm over two weeks. Worth labs.
Bringing the four-week chart with these flags lets the prescriber adjust intelligently rather than relying on the user's verbal recall.
Two boundaries.
This guide does not recommend Mounjaro for any specific person, indication, or dose. Mounjaro is FDA-approved for type 2 diabetes; off-label use for weight management exists and is common but is between you and your prescriber. miora does not prescribe and does not recommend titration schedules.
The guide also does not promise weight-loss outcomes. Individual response to Mounjaro varies widely; the average rates reported in the SURMOUNT trials are not guarantees. A good tracker helps you run the protocol you have been prescribed with cleaner data and earlier flags; it does not change the underlying response. This content is for informational purposes only and is not medical advice. Mounjaro requires prescription and clinician supervision.
98
